Adaptimmune Therapeutics Plc - ADAP STOCK NEWS

Adaptimmune Therapeutics (NASDAQ: ADAP) announced promising outcomes from its Phase 1 SURPASS trial, demonstrating significant anti-tumor activity across various cancers. Key findings include a 36% overall response rate and an 86% disease control rate, with a complete response reported in ovarian cancer. The ADP-A2M4CD8 therapy has displayed enhanced tumor cell killing and improved immune system engagement. The company is actively recruiting patients for this and a new Phase 2 trial targeting esophageal and EGJ cancers, indicating progress towards late-stage development.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) has announced a strategic collaboration with Genentech to develop allogeneic cell therapies for cancer. This agreement entails an upfront payment of $150 million, with an additional $150 million expected over five years, and potential milestone payments exceeding $3 billion. Adaptimmune will utilize its induced pluripotent stem cell (iPSC) platform for T-cell production, while Genentech will focus on TCR input and clinical development. The partnership is subject to clearance under antitrust laws and aims to broaden personalized cancer treatment approaches.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) presented updated data from its Phase 1 ADP-A2AFP trial for liver cancer at the International Liver Cancer Association meeting. The trial showed a disease control rate of 64%, with one patient achieving a complete response and two patients maintaining stable disease for over 16 weeks. The safety profile was deemed acceptable, with no significant hepatotoxicity reported. The ongoing expansion phase aims to treat up to 25 patients, suggesting continued potential for this cell therapy approach in advanced hepatocellular carcinoma.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported its Q2 2021 results, highlighting an overall response rate of 39.3% in synovial sarcoma from its SPEARHEAD-1 trial. The company plans to submit a Biologics License Application (BLA) for afami-cel next year. Revenue for Q2 was $3.1 million, a significant increase from $0.5 million in Q2 2020, driven by collaboration activities. However, R&D expenses rose to $28.9 million, leading to a net loss of $39.1 million. The company expects to be funded into early 2023.

Adaptimmune Therapeutics (Nasdaq:ADAP) will announce its Q2 2021 financial results on August 9, 2021, after market close. A live teleconference and webcast will follow at 4:30 p.m. EDT. The company focuses on developing innovative cancer immunotherapy products utilizing its SPEAR T-cell platform, designed to target solid tumors. Interested parties can access the press release on Adaptimmune's corporate website. Forward-looking statements regarding product development and clinical trials are included, highlighting associated risks and uncertainties.

Adaptimmune Therapeutics (Nasdaq:ADAP) announced promising initial data from its Phase 2 SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel) in treating synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Presented at ASCO, the trial reported a 39.3% overall response rate with an encouraging disease control rate of 86.2% in synovial sarcoma patients. Initial safety results indicate a favorable profile, mostly low-grade cytokine release syndrome. The company aims for a Biologics License Application (BLA) submission next year, bolstering hopes for a new treatment option in an unmet medical need.

Adaptimmune Therapeutics (Nasdaq: ADAP) announced preclinical data on its HiT targeting mesothelin at the ASGCT meeting. The HLA-independent TCR technology showed promising results, inducing complete tumor regression in a mouse model and outperforming a TRuC comparator. Notably, human T-cells expressing the HiT effectively killed mesothelin-expressing tumor cells, independent of CD8. Unlike the TRuC construct, the HiT was not neutralized by soluble mesothelin, highlighting its potential advantages for future cancer therapies.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced updates on May 6, 2021, highlighting progress in its clinical trials and financial performance for Q1 2021. Key developments include the initial data presentation from the SPEARHEAD-1 trial at ASCO, increased enrollment in the SURPASS and ADP-A2AFP trials, and a financial report showing $0.4 million in revenue. R&D expenses rose to $24.5 million. The company confirmed it has sufficient liquidity to fund operations into early 2023. The second target has been nominated under the co-development agreement with Astellas.

Adaptimmune Therapeutics (Nasdaq:ADAP) announced the upcoming presentation of initial preclinical data on its HLA Independent TCR (HiT) targeting mesothelin, co-developed with Astellas, at the ASGCT meeting. This will occur on May 11, 2021, during the Cancer - Immunotherapy session, with abstract #641 published online. Adaptimmune focuses on cell therapies for cancer, utilizing its SPEAR T-cell platform to combat various solid tumors. The release contains forward-looking statements, indicating potential risks related to product development and regulatory processes.